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Abstract
Background. The balANZ trial recently reported that
neutral pH, low glucose degradation product
(biocompatible) peritoneal dialysis (PD) solutions signiﬁ-
cantly delayed anuria and reduced peritonitis rates com-
pared with conventional solutions. This article reports a
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secondary outcome analysis of the balANZ trial with
respect to peritoneal membrane function.
Methods. Adult, incident PD patients with residual renal
function were randomized to receive either biocompatible
or conventional (control) PD solutions for 2 years. Peritoneal
equilibration tests were performed at 1, 6, 12, 18 and 24
months. Peritoneal small solute clearances and ultra-ﬁltration
(UF) were measured at 3, 6, 9, 12, 18 and 24 months.
Results. Of the 185 patients recruited into the trial, 85
patients in the Balance group and 82 patients in the control
group had peritoneal membrane function evaluated. Mean
4-h dialysate:plasma creatinine ratios (D:P Cr 4h) at 1 month
were signiﬁcantly higher in the Balance group compared
with controls (0.67 ± 0.10 versus 0.62 ± 0.10, P = 0.002).
Over the 2-year study period, mean D:P Cr 4 h measure-
ments remained stable in the Balance group but increased
signiﬁcantly in controls [difference −0.004 per month, 95%
conﬁdence interval (95% CI) −0.005 to −0.002, P < 0.001].
Similar results were obtained for dialysate glucose ratios
(D/D0 glucose). Peritoneal UF was signiﬁcantly lower in
the Balance group than in controls at 3 and 6 months. Over
the 2-year study period, peritoneal UF increased signiﬁ-
cantly in the Balance group but remained stable in controls
(difference 24 mL/day/month, 95% CI 9–39, P = 0.002).
No differences in peritoneal small solute clearances, pre-
scribed dialysate ﬁll volumes or peritoneal glucose exposure
were observed between the two groups.
Conclusions. Biocompatible and conventional PD solutions
exert differential effects on peritoneal small solute transport
rate and UF over time. Adequately powered trials assessing
the impact of these differential membrane effects on PD tech-
nique and patient survival rates are warranted.
Keywords: biocompatibility; glucose degradation products; outcomes;
peritoneal dialysis; peritoneal equilibration test
Introduction
Approximately 200 000 end-stage renal failure patients
worldwide (or 11% of the global dialysis population)
utilize peritoneal dialysis (PD) for life-sustaining mainten-
ance renal replacement therapy [1]. Most published obser-
vational cohort studies suggest that the medium-term
survival (up to 3–4 years) of patients treated with PD is at
least comparable, and possibly superior, to that of patients
receiving haemodialysis (HD) [2–6]. However, PD is associ-
ated with a higher rate of technique failure than HD [7].
A large body of basic research in animal models and
peritoneal cell culture systems has suggested that a major
contributor to the high technique failure rate of PD is the
bio-incompatible nature of conventional PD ﬂuids, par-
ticularly as a result of their acidic pH (5.0–5.8) and high
concentration of glucose degradation products (GDP) gen-
erated during the heat sterilization process [8]. Such ‘un-
physiological’ characteristics may have both a negative
impact on peritoneal cell populations and a pro-ﬁbrotic
effect on the peritoneal membrane [9–13]. In particular,
experimental and clinical exposure of the peritoneal mem-
brane to conventional PD solutions engenders signiﬁcant
histopathological changes over time, including loss of the
surface mesothelial cell layer, thickening of the sub-me-
sothelial compact zone and the development of a pro-
gressive vasculopathy [14, 15]. Most of these adverse
effects have been largely abrogated by the use of neutral-
buffered, low GDP ﬂuids in in vivo studies [8, 11, 16, 17].
Subsequent short-term, small, clinical studies have demon-
strated that the use of low GDP ﬂuids in PD patients is
accompanied by signiﬁcant improvements in the efﬂuent
biomarkers of peritoneal membrane integrity, stable mem-
brane function and reductions in peritoneal membrane
inﬂammatory response [18–25]. However, evidence of a
beneﬁcial effect on the morphological and functional
changes associated with long-term exposure to PD ﬂuids
is not yet available.
The recently published balANZ randomized controlled
trial [26] found that the administration of a neutral pH,
lactate-buffered, low GDP ﬂuid (Balance®) to incident PD
patients was associated with an appreciable reduction in
peritonitis rates and a signiﬁcant delay in the onset of
anuria compared with conventional, standard, lactate-buf-
fered PD solutions (stay.safe®). In order to further evalu-
ate the impact of biocompatible ﬂuid on PD outcomes,
this secondary analysis aimed to determine whether
neutral pH, low GDP (biocompatible) PD ﬂuid exerted
beneﬁcial effects on peritoneal membrane permeability,
small solute clearance and ultra-ﬁltration (UF) over a 2-
year period compared with conventional dialysate.
Materials and methods
The study design and methodology [27] and the main results of the
balANZ trial [26] have been described previously. The study was con-
ducted in accordance with the ethical principles of the Declaration of
Helsinki, the Good Clinical Practice guidelines of the International Con-
ference of Harmonization, and local regulatory requirements. It was ap-
proved by ethics committees at all participating centres and all patients
provided written informed consent prior to trial participation.
The study was an investigator-initiated, prospective, open-label, ran-
domized controlled Phase 4 trial involving 16 centres across Australia,
New Zealand and Singapore. It included incident, adult PD patients who
had both a residual measured glomerular ﬁltration rate ≥5 mL/min/1.73 m2
and a measured urine volume ≥400 mL/day. Pregnant or breast-feeding
patients, individuals expected to die within 12 months, patients partici-
pating in trials targeting residual renal function in PD or those with
a signiﬁcant cancer history in the past 5 years, acute infection at enrol-
ment, contra-indications to PD, any physical or mental disorder that
appreciably hampered study protocol compliance or known or sus-
pected allergy to trial product or related products were excluded. Par-
ticipants were randomized 1:1 to receive either neutral pH, lactate-
buffered, low GDP solution (Balance®) or conventional, standard,
lactate-buffered solution (stay.safe®). Randomization was performed
centrally via a web-based system and was stratiﬁed for both centre and
presence or absence of diabetic nephropathy. Patients in each trial arm
were treated according to local PD unit management protocols. Icodex-
trin and automated PD were permitted in both groups. Each patient
was followed for 24 months. The primary outcome measure of the
study was residual renal function decline. This article focuses on the
secondary outcome measures of peritoneal transport status, peritoneal
small solute clearance and peritoneal UF.
Dialysate: plasma creatinine ratio at 4 h (D:P Cr 4 h) and the ratio of
dialysate glucose concentrations at 4 and 0 h (D/D0 glucose) were deter-
mined by standard peritoneal equilibration test (PET) [28] at 1, 6, 12, 18
and 24 months. Weekly peritoneal creatinine clearance (CpCr) and urea
clearance (CpUr) were calculated from 24-h dialysate collections at 3, 6,
9, 12, 18 and 24 months, normalized for body surface area (BSA) and
expressed as L/week/1.73 m2. BSA was calculated using the Du Bois










formula [29]. Peritoneal UF during the 24-h collection was also recorded
and expressed as mL/day. Peritoneal glucose exposure was calculated ac-
cording to the method described by Davies et al. [7]. Peritoneal UF was
normalized for peritoneal glucose exposure on the day that the UF was
measured.
Statistical analysis
Results were expressed as frequencies (percentages), mean ± standard
deviation or median [range], depending on data distribution. Group com-
parisons were performed by χ2-test, unpaired t-test or Mann–Whitney
test, as appropriate. For the outcome measures of changes in peritoneal
membrane permeability, small solute clearance and UF over time, a
mixed effects General Linear Model was ﬁtted for each outcome variable
with treatment group, centre and presence or absence of diabetic nephro-
pathy as ﬁxed effects terms. Patient identiﬁcation number was ﬁtted as a
‘random’ term in the model, along with time and intercept. In this way,
the model provided estimates of the rate of change (slope) in the
outcome measure for each patient allowing them to also have a different
intercept (starting level). From these data, an overall estimate of the rate
of change in each treatment group was determined, corrected for the
ﬁxed-effects terms. The data were assumed to be normally distributed
and to change in a linear fashion. Differences in the rate of change
between the intervention and control groups were analysed on an inten-
tion-to-treat basis. Mixed models assume missing at random patterns to
cater for missed visits or withdrawal for any reason other than those
related to treatment. Data were analysed by Statistical Revelations Pty




One hundred and eighty-ﬁve patients were randomized to
receive either Balance (n = 92) or control (stay.safe) ﬂuid
(n = 93). Of these, 85 patients in the Balance group and
82 patients in the control group had peritoneal membrane
function tests. As previously reported [26], the two groups
were well matched for all baseline characteristics, including
age, gender, end-stage renal failure cause, presence of cardi-
ovascular disease, body mass index, initial dialysis modality,
prescribed medications, blood pressure, prescribed dialysate
volumes and glucose exposure, residual renal function and
urine volume and laboratory parameters (serum albumin,
calcium and haemoglobin). At baseline, the median [range]
prescribed dialysate ﬁll volumes were 8000 [2000–10 000]
mL/day in the Balance group and 8000 [2000–8700]
mL/day in the stay.safe group (P = not signiﬁcant). The per-
itoneal glucose exposures were 121.5 ± 35.3 and 123.6 ±
36.3 g/day, respectively (P = not signiﬁcant).
Peritoneal transport status
The results of PETs in each group at 1, 6, 12, 18 and 24
months are shown in Table 1. Mean D:P Cr 4 h values at
1 month were signiﬁcantly higher in the Balance group
compared with the control group (0.67 ± 0.10 versus 0.62
± 0.10, P = 0.002). The respective proportions of high,
high average, low average and low transporters were 8,
57, 29 and 6% in the Balance group and 5, 31, 58 and
7% in the stay.safe group (P = 0.001), respectively. Over
the duration of the study, mean D:P Cr 4 h measurements
remained stable in the Balance group [0.001 per month,
95% conﬁdence interval (95% CI) −0.001 to 0.002] but
increased signiﬁcantly in the stay.safe group (0.004 per
month, 95% CI 0.003–0.005) (Figure 1). The difference
in D:P Cr 4h gradients over time between the two groups
was statistically signiﬁcant (−0.004 per month, 95% CI
−0.005 to −0.002, P < 0.001, Figure 1). At 6 months, the
respective proportions of high, high average, low average
and low transporters were 9, 53, 35 and 3% in the
Balance group and 1, 49, 44 and 6% in the stay.safe
group (P = 0.11). No differences in peritoneal transport
status were observed between the Balance and stay.safe
groups at 12 months (P = 0.63) or 24 months (P = 0.65).
Similar results were observed for D/D0 glucose
measurements. Mean values at 1 month were lower in the
Balance group than in the stay.safe group (0.39 ± 0.08
versus 0.43 ± 0.08, P = 0.003). Over the duration of the
study, mean D/D0 glucose measurements remained stable
in the Balance group (0.001 per month, 95% CI −0.000
to 0.002) but decreased signiﬁcantly in the stay.safe group
(−0.002 per month, 95% CI −0.003 to −0.001)
(Figure 2). The difference in D:P Cr 4 h gradients
between the two groups was statistically signiﬁcant
(0.002 per month, 95% CI 0.001–0.004, P < 0.01).
Peritoneal small solute clearance
The results of peritoneal small solute clearance measure-
ments in each group at 3, 6, 9, 12, 18 and 24 months are
shown in Table 1. Peritoneal CpCr measurements were
comparable between the two groups over time. CpCr
values increased over time in both the Balance group
(0.33 L/week/1.73 m2/month, 95% CI 0.21–0.46) and the
control group (0.37 L/week/1.73 m2/month, 95% CI
0.25–0.49) (Figure 3). The difference between the groups
was not statistically signiﬁcant (0.04 L/week/1.73 m2/
month, 95% CI −0.21 to 0.14, P = 0.79).
Similar results were observed for peritoneal CpUr
measurements. CpUr values increased over time in both
the Balance group (0.35 L/week/1.73 m2/month, 95% CI
0.19–0.50) and the control group (0.26 L/week/1.73 m2/
month, 95% CI 0.11–0.41) (Figure 4). The difference
between the groups was not statistically signiﬁcant (0.08
L/week/1.73 m2/month, 95% CI −0.13 to 0.30, P = 0.45).
Peritoneal ultra-ﬁltration
The results of peritoneal UF in each group at 3, 6, 9, 12,
18 and 24 months are shown in Table 1. Peritoneal UF
was signiﬁcantly lower in the Balance group than in con-
trols at 3 and 6 months. These lower UF volumes in the
biocompatible group coincided with higher urine volumes
[26]. Over the course of the study, peritoneal UF in-
creased signiﬁcantly in the Balance group (16 mL/day/
month, 95% CI 5–27) but remained stable in the stay.safe
group (−8 mL/day/month, 95% CI −19 to 2) (Figure 5).
The difference in gradients between the groups was
statistically signiﬁcant (24 mL/day/month, 95% CI 9–39,
P = 0.002). This difference persisted after normalization
of peritoneal UF for glucose exposure (0.08 mL/day/g/
month, 95% CI 0.03–0.14, P = 0.004) (Figure 6).










Table 1. Measurements of peritoneal small solute clearance, UF and transport status over time in balANZ trial participants
































n 85 78 75 74 68 68 62 65 53 56 40 48
Median 52 56 54 56 55* 58 56 59 56 58 59 61




n 84 78 75 74 68 70 62 66 53 56 40 48
Median 40 39 41 43 39 43 43 44 42 46 44 49
[min, max] [11, 54] [2, 67] [11, 58] [12, 71] [20, 74] [17, 79] [21, 63] [20, 77] [25, 69] [21, 69] [23, 62] [19, 70]
UF (mL/day) N/A N/A
n 85 79 75 74 68 70 62 66 53 56 40 48
Median 700* 1090 850* 1015 913* 1233 955 1150 1100 951 900 993
[min, max] [−700,
3500]














D:P Cr 4 h N/A N/A N/A N/A
n 83 82 75 73 60 66 51 56 37 47
Mean ± SD 0.67 ± 0.10* 0.62 ± 0.10 0.67 ± 0.10* 0.64 ± 0.09 0.67 ± 0.10 0.67 ± 0.09 0.67 ± 0.09 0.68 ± 0.11 0.67 ± 0.09 0.70 ± 0.08
D/D0 glucose 4 h N/A N/A N/A N/A
n 83 82 75 73 59 66 50 56 37 47
Mean ± SD 0.39 ± 0.08* 0.43 ± 0.08 0.40 ± 0.08* 0.43 ± 0.07 0.40 ± 0.08 0.40 ± 0.08 0.98 ± 0.15 0.42 ± 0.15 0.41 ± 0.07 0.39 ± 0.08
4 h UF during PET
(mL)
N/A N/A N/A N/A
n 83 82 75 73 60 66 51 56 37 47
Median 300* 354 300* 400 260* 400 300 345 300 350
[min, max] [−200, 900] [−100,
1085]
[−110, 900] [−100, 1010] [−200, 750] [−80, 650] [−350, 900] [−250, 988] [−270, 900] [10, 863]
24 h dialysate ﬁll
volume (mL/day)































Mean ± SD 139.1 ± 44.4 126.5 ± 35.5 142.1 ± 43.5 133.9 ± 36.9 143.7 ± 40.5 140.5 ± 43.5 149.2 ± 42.5 146.3 ± 46.2 150.0 ± 41.0 150.9 ± 48.5 158.4 ± 49.2 157.4 ± 52.3 161.7 ± 54.1 157.4 ± 52.3
Results are presented as mean ± SD or median [range], depending on data distribution.
*P < 0.05 versus Stay.safe (control).
CpCr, peritoneal creatinine clearance; CpUr, peritoneal urea clearance; D/D0 glucose, ratio of 4 h to initial dialysate glucose concentrations; D:P Cr 4 h, dialysate:plasma creatinine ratio at 4 h; N/A, not available; PET, peritoneal
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Discussion
This investigator-initiated, multi-centre, multi-country,
prospective, open-label, randomized controlled Phase 4
trial involving 16 centres across Australia, New Zealand
and Singapore demonstrated that prescription of neutral
pH, lactate-buffered, low GDP (Balance) solution in PD
patients was associated with an initially higher peritoneal
membrane solute transport rate and lower peritoneal UF
rate compared with controls. Moreover, whereas these par-
ameters remained stable in the biocompatible group over
the 2-year follow-up period of the study, there was a pro-
gressive increase in peritoneal membrane permeability in
controls. Peritoneal small solute clearance increased at
comparable rates over time in both groups.
Serial elevations in peritoneal solute transport charac-
teristics and deterioration in peritoneal UF over time have
been reported in patients treated with conventional dialy-
sis ﬂuids and have been attributed to the bio-incompatible
nature of these solutions [30, 31]. However, while in vitro
studies have reported that biocompatible ﬂuid adminis-
tration was associated with signiﬁcant improvements in
Fig. 1. Change in D:P Cr 4 h over time in the balance (A) and control (B) groups over 2 years. Grey lines represent individual patient measurements
while solid lines represent predicted gradients. The difference in gradients between the two groups was statistically signiﬁcant (P < 0.001).
Fig. 2. Change in D/D0 glucose over time in the Balance (A) and control (B) groups over 2 years. Grey lines represent individual patient measurements
while solid lines represent predicted gradients. The difference in gradients between the two groups was statistically signiﬁcant (P < 0.01).
Fig. 3. Change in peritoneal CpCr over time in the Balance (A) and control (B) groups over 2 years. Grey lines represent individual
patient measurements while solid lines represent predicted gradients. The difference in gradients between the two groups was not statistically
signiﬁcant (P = 0.69).










peritoneal cell viability, function and structure, clinical
trials of biocompatible ﬂuids on peritoneal membrane
function have been both limited and conﬂicting. In
keeping with the ﬁndings of the present investigation, the
Euro Balance trial [19], a multi-centre, open-label, pro-
spective randomized cross-over study of Balance versus
standard PD ﬂuid over two 12-week periods, observed
signiﬁcant increases in D:P Cr 4 h measurements in
patients randomized to Balance. This rise in peritoneal
permeability was associated with a signiﬁcant fall in per-
itoneal UF. In a randomized controlled trial of a nutrineal,
extraneal and physioneal (NEPP) regimen versus conven-
tional dialysis ﬂuid in 63 incident PD patients, Le Poole
found that the lower GDP NEPP regimen was associated
with an increase in peritoneal solute transport rate. Simi-
larly, Kim et al. [23] observed signiﬁcantly higher D:P Cr
4 h values in 48 patients randomly allocated to Balance
solution compared with 43 control patients receiving con-
tinuous ambulatory peritoneal dialysis / Dialyse Périto-
néale Continue Ambulatoire ﬂuid (Balnet study).
Moreover, D:P Cr 4 h remained stable in the biocompati-
ble group over a period of 12 months. However, in
Fig. 5. Change in peritoneal UF over time in the Balance (A) and control (B) groups over 2 years. Grey lines represent individual
patient measurements while solid lines represent predicted gradients. The difference in gradients between the two groups was statistically signiﬁcant
(P = 0.002).
Fig. 4. Change in peritoneal CpUr over time in the Balance (A) and control (B) groups over 2 years. Grey lines represent individual
patient measurements while solid lines represent predicted gradients. The difference in gradients between the two groups was not statistically
signiﬁcant (P = 0.45).
Fig. 6. Change in peritoneal UF, normalized for peritoneal glucose exposure, over time in the Balance (A) and control (B) groups over 2 years. Grey
lines represent individual patient measurements while solid lines represent predicted gradients. The difference in gradients between the two groups
was statistically signiﬁcant (P = 0.004).










contrast to the ﬁndings of the present study and those of
other studies [32], Kim et al. reported a signiﬁcant fall in
D:P Cr 4 h over time in patients receiving conventional
dialysis solutions. Peritoneal UF rates also tended to fall
in the biocompatible group compared with controls,
although this did not reach statistical signiﬁcance (P =
0.09). Haag-Weber also observed a tendency to lower per-
itoneal UF in the biocompatible group (P = 0.10) without
any signiﬁcant changes in PET measurements, although
these observations did not allow for the signiﬁcant differ-
ences in overﬁll between biocompatible and standard PD
solutions. On the other hand, two randomized controlled
clinical trials [21, 33] have reported no changes in either
PET measurements or peritoneal UF between biocompati-
ble and conventional dialysates, while two other studies
[34, 35] found no change in D:P Cr 4 h but a signiﬁcant
increase in peritoneal UF in association with biocompatible
ﬂuid use. The apparent disparities in ﬁndings between
these studies and those of the present investigation may be
explained by the fact that the other trials often suffered
from a number of important limitations including insufﬁ-
cient statistical power due to small numbers, short-term
follow-up, high drop-out rates, treatment-associated
changes in ﬂuid status, use of solutions with variable GDP
content, sub-optimal methodological quality, lack of adjust-
ment for peritoneal glucose exposure, enrolment of preva-
lent PD patients and single-centre designs. In contrast, our
multi-centre study represents the largest and longest
running randomized controlled trial to date evaluating the
effects of biocompatible ﬂuids on peritoneal membrane
transport, small solute clearance and glucose-adjusted UF.
Similar to the results of the balANZ trial, the few pre-
viously published randomized controlled trials that have
examined peritoneal small solute clearances have not
observed a signiﬁcant effect of biocompatible ﬂuids
[20, 23, 34]. However, Choi et al. [35] and Williams
et al. [19] did report signiﬁcant increases in peritoneal
CpUr in patients receiving biocompatible ﬂuids compared
with controls, although peritoneal CpCrs were not differ-
ent between the two groups. The similar overall ﬁndings
between trials of comparable peritoneal small solute clear-
ances in patients receiving biocompatible or conventional
PD solutions in spite of variable observed differences
in peritoneal solute transport rates may be potentially
explained by the fact that PD patients’ prescriptions were
titrated to achieve common small solute clearance targets
between the two groups.
The observed higher initial peritoneal solute transport
rate in patients receiving biocompatible ﬂuids in the
balANZ trial, as evidenced by higher initial D:P Cr 4 h
and lower initial D/D0 glucose values, may be potentially
explained by alterations in peritoneal vascular surface
area. Previous studies in animals have observed that con-
ventional, acidic pH, lactate-buffered 4.25% glucose re-
sulted in a doubling of arteriolar ﬂow and a 20% increase
of perfused capillary length per area, while administration
of a pH-neutral, bicarbonate-buffered, low GDP solution
did not affect haemodynamic parameters [36]. Alterna-
tively, administration of biocompatible ﬂuids may inﬂu-
ence local peritoneal membrane production of vasoactive
cytokines, such as vascular endothelial growth factor and
nitric oxide [19, 37]. The impact of these changes in per-
itoneal solute transport rate and UF on long-term patient-
level outcomes remains uncertain. We have previously
reported that technique and patient survival rates were
comparable between the Balance and control groups in
the balANZ trial [26], although the study had insufﬁcient
statistical power to exclude Type-2 statistical errors for
these end-points.
The strengths of this study include its very large
sample size, 2-year follow-up period, trial design and in-
volvement of participants from a range of centres and
countries with varying approaches to PD. This greatly en-
hanced the external validity of our ﬁndings. Randomiz-
ation allocation was appropriately concealed and stratiﬁed
for PD unit to mitigate against centre effects. The Balance
and stay.safe groups were well balanced with respect to
baseline demographic and clinical characteristics, thereby
attesting to the success of the randomization process.
These strengths must be weighed up against the study’s
limitations, the principal one of which was that the rela-
tively high drop-out rate (45% over 2 years) may have
introduced informative censoring bias. However, the
numbers of, and reasons for drop-out in each group were
comparable. Moreover, missing peritoneal membrane tests
due to withdrawal or non-treatment-related factors were
catered for in the mixed effects general linear model
analysis used in this study. The open-label design may
have introduced the possibility of co-intervention bias.
Observer bias could also not be excluded, although this
was countered by the use of clearly deﬁned, objective per-
itoneal membrane solute transport and UF measures. As
with other studies in this area [19, 23, 30], a reciprocal
relationship was observed in the balANZ trial between
peritoneal UF and urine volume suggesting that some of
the fall in peritoneal UF observed in the biocompatible
group may have been explained by volume-driven
changes. Overﬁll was not accounted for in the present
study, although the difference in overﬁll between Balance
and stay.safe is very small (∼20 mL).
In conclusion, administration of a neutral pH, lactate-
buffered, low GDP ﬂuid (Balance) to incident PD patients
was associated with higher peritoneal solute transport
rates, which then remained stable over the 2-year follow-
up period. Peritoneal UF was initially lower but increased
signiﬁcantly over time. In contrast, patients receiving con-
ventional PD solutions experienced progressive increases
in peritoneal solute transport rate and stable peritoneal UF
over time. Future, adequately powered randomized con-
trolled trials investigating the impact of biocompatible
ﬂuid-induced changes in peritoneal membrane function
on PD technique survival are warranted.
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Abstract
Background. The Beck Depression Inventory (BDI) is a
standard and validated questionnaire to screen for depress-
ive symptoms in chronic dialysis patients, but is relatively
extensive to use repeatedly in clinical practice. We investi-
gated whether the ﬁve-item Mental Health Inventory (MHI-
5) of the 36-item Short-Form Health Survey Question-
naire (SF-36) could be applied to screen for depressive
symptoms in dialysis patients. Moreover, we determined
the optimal MHI-5 cut-off score to assess depressive
symptoms.
Methods. Chronic dialysis patients from three centres
ﬁlled out the SF-36 and the BDI. A receiver operating
characteristic (ROC) curve was constructed for the MHI-5
score with BDI ≥16 as reference standard to (i) calculate the
area under the curve to determine whether the MHI-5 could
be considered as a useful screening instrument for depress-
ive symptoms and (ii) proxy the optimal cut-off score of the
MHI-5 to assess depressive symptoms. The optimal cut-off
score was determined by the value for which the sum of
sensitivity and speciﬁcity had an optimum.
Results. Of 133 included patients, 23% had depressive
symptoms as determined with BDI ≥16. The correlation of
the BDI with MHI-5 was –0.64. The area under the ROC
curve was 0.82 (95% conﬁdence interval 0.74–0.90). The
optimal cut-off point of the MHI-5 was 70. MHI-5 ≤70 had
77 sensitivity, 72 speciﬁcity, 44 positive predicting value
and 91% negative predicting value with the presence of
depressive symptoms determined with BDI ≥16.
Conclusions. The MHI-5 may help clinicians to screen for
depressive symptoms in dialysis patients without using an
additional depression screening questionnaire once the SF-
36 is completed. A cut-off value of 70 can be used safely
for the purposes of screening applications.
Keywords: depressive symptoms; dialysis patients; mental health
inventory; screening; SF-36
Introduction
Depression is the most common psychiatric disorder
among chronic dialysis patients [1]. It is of great impor-
tance that depressive symptoms are successfully recognized
and treated. Depressive symptoms diminish patient’s
quality of life and are independently associated with an in-
creased risk of hospitalization [2, 3]. In addition, depressive
symptoms pose a risk factor for both cardiovascular and
non-cardiovascular mortality [4–6]. Hence, the National
Kidney Foundation, Disease Outcomes Quality Initiative
(NKF KDOQI) guideline for cardiovascular disease in
dialysis the patients recommends that the patient’s psycho-
logical state should be assessed at least biannually with
speciﬁc focus on the presence of depressive symptoms [7].
The assessment of depressive symptoms is frequently
performed using self-reported depression screening tools,
whereupon patients who are screened positive are
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